BeiGene, Ltd. (BGNE)
Pre-Market:
| Previous Close | 131.86 |
| Open | 131.40 |
| Bid | 131.86 x 100 |
| Ask | 132.85 x 100 |
| Day's Range | 131.40 - 136.00 |
| 52 Week Range | 131.28 - 266.67 |
| Volume | |
| Avg. Volume | 249,924 |
| Market Cap | 14.459B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 272.77 |
Simply Wall St.Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
Insider Monkey30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Business WireBeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in t
